Pharmacological approaches to the management of cognitive dysfunction in schizophrenia

Philip D Harvey, Margaret M. McClure

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Cognitive dysfunction is a core feature of schizophrenia as deficits that are present in the majority of patients with schizophrenia frequently precede the onset of other symptoms and persist even after other symptoms have been effectively treated. The use of atypical antipsychotics has produced some small improvements, although the need for adjunctive treatment specifically targeting cognitive dysfunction is gaining widespread acceptance. Animal models and some small clinical trials have yielded results that are promising but not definitive. Psychosocial interventions have also met with some success in ameliorating some cognitive limitations. The mixed results of pharmacological interventions are most likely to be as a result of a combination of methodological flaws of many studies, poor outcome measures, dose administration effects and problems with the agents themselves.

Original languageEnglish
Pages (from-to)1465-1473
Number of pages9
JournalDrugs
Volume66
Issue number11
DOIs
StatePublished - Aug 23 2006
Externally publishedYes

Fingerprint

Antipsychotic Agents
Schizophrenia
Animals
Pharmacology
Defects
Animal Models
Outcome Assessment (Health Care)
Clinical Trials
Cognitive Dysfunction
Therapeutics

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Pharmacological approaches to the management of cognitive dysfunction in schizophrenia. / Harvey, Philip D; McClure, Margaret M.

In: Drugs, Vol. 66, No. 11, 23.08.2006, p. 1465-1473.

Research output: Contribution to journalArticle

Harvey, Philip D ; McClure, Margaret M. / Pharmacological approaches to the management of cognitive dysfunction in schizophrenia. In: Drugs. 2006 ; Vol. 66, No. 11. pp. 1465-1473.
@article{1000e8253a824e9bb8a07ba52801637e,
title = "Pharmacological approaches to the management of cognitive dysfunction in schizophrenia",
abstract = "Cognitive dysfunction is a core feature of schizophrenia as deficits that are present in the majority of patients with schizophrenia frequently precede the onset of other symptoms and persist even after other symptoms have been effectively treated. The use of atypical antipsychotics has produced some small improvements, although the need for adjunctive treatment specifically targeting cognitive dysfunction is gaining widespread acceptance. Animal models and some small clinical trials have yielded results that are promising but not definitive. Psychosocial interventions have also met with some success in ameliorating some cognitive limitations. The mixed results of pharmacological interventions are most likely to be as a result of a combination of methodological flaws of many studies, poor outcome measures, dose administration effects and problems with the agents themselves.",
author = "Harvey, {Philip D} and McClure, {Margaret M.}",
year = "2006",
month = "8",
day = "23",
doi = "10.2165/00003495-200666110-00004",
language = "English",
volume = "66",
pages = "1465--1473",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "11",

}

TY - JOUR

T1 - Pharmacological approaches to the management of cognitive dysfunction in schizophrenia

AU - Harvey, Philip D

AU - McClure, Margaret M.

PY - 2006/8/23

Y1 - 2006/8/23

N2 - Cognitive dysfunction is a core feature of schizophrenia as deficits that are present in the majority of patients with schizophrenia frequently precede the onset of other symptoms and persist even after other symptoms have been effectively treated. The use of atypical antipsychotics has produced some small improvements, although the need for adjunctive treatment specifically targeting cognitive dysfunction is gaining widespread acceptance. Animal models and some small clinical trials have yielded results that are promising but not definitive. Psychosocial interventions have also met with some success in ameliorating some cognitive limitations. The mixed results of pharmacological interventions are most likely to be as a result of a combination of methodological flaws of many studies, poor outcome measures, dose administration effects and problems with the agents themselves.

AB - Cognitive dysfunction is a core feature of schizophrenia as deficits that are present in the majority of patients with schizophrenia frequently precede the onset of other symptoms and persist even after other symptoms have been effectively treated. The use of atypical antipsychotics has produced some small improvements, although the need for adjunctive treatment specifically targeting cognitive dysfunction is gaining widespread acceptance. Animal models and some small clinical trials have yielded results that are promising but not definitive. Psychosocial interventions have also met with some success in ameliorating some cognitive limitations. The mixed results of pharmacological interventions are most likely to be as a result of a combination of methodological flaws of many studies, poor outcome measures, dose administration effects and problems with the agents themselves.

UR - http://www.scopus.com/inward/record.url?scp=33747329318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747329318&partnerID=8YFLogxK

U2 - 10.2165/00003495-200666110-00004

DO - 10.2165/00003495-200666110-00004

M3 - Article

C2 - 16906778

AN - SCOPUS:33747329318

VL - 66

SP - 1465

EP - 1473

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 11

ER -